LISCure Biosciences Inc., a biotech company that focuses on developing bacteria-mediated immunotherapy, has completed $21 million of a Series B funding round.
Participants include institutional investors, venture capitals, and KOSDAQ listed companies (as strategic investors).
This funding round will help LISCure further develop its pipeline and enhance its R&D capabilities of key technologies. It is planning to expand indications of each program through the US subsidy, working with global research institutes.
Founded in 2018, LISCure Biosciences was established to develop a “bacteria-mediated immunotherapy” that can treat patients by itself or be used in combination with other drugs for major indications such as tumors, neurological degeneration, autoimmune, and metabolic diseases.
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.